RCM
PRLD icon

RA Capital Management’s Prelude Therapeutics PRLD Stock Holding History

RA Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.5M Buy
+6,475,882
New +$28.2M 0.3% 50

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

RA Capital Management's PRLD Position: Q2 2026 in Review

RA Capital Management opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 6,475,882 shares worth $34.5M. The stake represents 0.3% of the portfolio and ranks #50 among its holdings.

68 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • RA Capital Management held 6,475,882 shares of Prelude Therapeutics worth $34.5M as of Q2 2026.
  • Prelude Therapeutics was a new RA Capital Management position in Q2 2026.
  • Prelude Therapeutics made up 0.3% of RA Capital Management's portfolio in Q2 2026, its #50 holding.
  • 68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.